• Je něco špatně v tomto záznamu ?

Dexrazoxane provided moderate protection in a catecholamine model of severe cardiotoxicity

L. Zatloukalová, T. Filipský, P. Mladěnka, V. Semecký, K. Macáková, M. Holečková, J. Vávrová, V. Palicka, R. Hrdina,

. 2012 ; 90 (4) : 473-84.

Jazyk angličtina Země Kanada

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc12034641

Positive effects of dexrazoxane (DEX) in anthracycline cardiotoxicity have been mostly assumed to be associated with its iron-chelating properties. However, this explanation has been recently questioned. Iron plays also an important role in the catecholamine cardiotoxicity. Hence in this study, the influence of DEX on a catecholamine model of acute myocardial infarction (100 mg/kg of isoprenaline by subcutaneous injection) was assessed: (i) the effects of an intravenous dose of 20.4 mg/kg were analyzed after 24 h, (ii) the effects were monitored continuously during the first two hours after drug(s) administration to examine the mechanism(s) of cardioprotection. Additional in vitro experiments on iron chelation/reduction and influence on the Fenton chemistry were performed both with isoprenaline/DEX separately and in their combination. DEX partly decreased the mortality, reduced myocardial calcium overload, histological impairment, and peripheral haemodynamic disturbances 24 h after isoprenaline administration. Continuous 2 h experiments showed that DEX did not influence isoprenaline induced atrioventricular blocks and had little effect on the measured haemodynamic parameters. Its protective effects are probably mediated by inhibition of late myocardial impairment and ventricular fibrillation likely due to inhibition of myocardial calcium overload. Complementary in vitro experiments suggested that iron chelation properties of DEX apparently did not play the major role.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc12034641
003      
CZ-PrNML
005      
20121206123048.0
007      
ta
008      
121023s2012 xxc f 000 0|eng||
009      
AR
024    7_
$a 10.1139/y2012-009 $2 doi
035    __
$a (PubMed)22439652
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxc
100    1_
$a Zatloukalová, Libuše $u Charles University in Prague, Department of Pharmacology and Toxicology, Heyrovského, Hradec Králové, Czech Republic.
245    10
$a Dexrazoxane provided moderate protection in a catecholamine model of severe cardiotoxicity / $c L. Zatloukalová, T. Filipský, P. Mladěnka, V. Semecký, K. Macáková, M. Holečková, J. Vávrová, V. Palicka, R. Hrdina,
520    9_
$a Positive effects of dexrazoxane (DEX) in anthracycline cardiotoxicity have been mostly assumed to be associated with its iron-chelating properties. However, this explanation has been recently questioned. Iron plays also an important role in the catecholamine cardiotoxicity. Hence in this study, the influence of DEX on a catecholamine model of acute myocardial infarction (100 mg/kg of isoprenaline by subcutaneous injection) was assessed: (i) the effects of an intravenous dose of 20.4 mg/kg were analyzed after 24 h, (ii) the effects were monitored continuously during the first two hours after drug(s) administration to examine the mechanism(s) of cardioprotection. Additional in vitro experiments on iron chelation/reduction and influence on the Fenton chemistry were performed both with isoprenaline/DEX separately and in their combination. DEX partly decreased the mortality, reduced myocardial calcium overload, histological impairment, and peripheral haemodynamic disturbances 24 h after isoprenaline administration. Continuous 2 h experiments showed that DEX did not influence isoprenaline induced atrioventricular blocks and had little effect on the measured haemodynamic parameters. Its protective effects are probably mediated by inhibition of late myocardial impairment and ventricular fibrillation likely due to inhibition of myocardial calcium overload. Complementary in vitro experiments suggested that iron chelation properties of DEX apparently did not play the major role.
650    _2
$a zvířata $7 D000818
650    _2
$a vápník $x metabolismus $7 D002118
650    _2
$a kardiotonika $x farmakologie $x terapeutické užití $7 D002316
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a hemodynamika $x účinky léků $7 D006439
650    _2
$a železo $x metabolismus $7 D007501
650    _2
$a chelátory železa $x farmakologie $7 D007502
650    _2
$a isoprenalin $x antagonisté a inhibitory $7 D007545
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a infarkt myokardu $x chemicky indukované $x farmakoterapie $7 D009203
650    _2
$a myokard $x metabolismus $x patologie $7 D009206
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a potkani Wistar $7 D017208
650    _2
$a razoxan $x farmakologie $x terapeutické užití $7 D011929
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Filipský, Tomáš
700    1_
$a Mladěnka, Přemysl
700    1_
$a Semecký, Vladimír
700    1_
$a Macáková, Kateřina
700    1_
$a Holečková, Magdalena
700    1_
$a Vávrová, Jaroslava
700    1_
$a Palicka, Vladimir
700    1_
$a Hrdina, Radomír
773    0_
$w MED00001020 $t Canadian journal of physiology and pharmacology $x 1205-7541 $g Roč. 90, č. 4 (2012), s. 473-84
856    41
$u https://pubmed.ncbi.nlm.nih.gov/22439652 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a
990    __
$a 20121023 $b ABA008
991    __
$a 20121206123121 $b ABA008
999    __
$a ok $b bmc $g 956651 $s 792138
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2012 $b 90 $c 4 $d 473-84 $i 1205-7541 $m Canadian journal of physiology and pharmacology $n Can J Physiol Pharmacol $x MED00001020
LZP    __
$a Pubmed-20121023

Najít záznam

Citační ukazatele

Nahrávání dat ...

    Možnosti archivace